In patients with NSCLC, increased PD-L1 expression is associated with poor prognosis 16 and the overall survival (OS) of patients might be prolonged by inhibiting the PD-1/PD-L1 signaling axis 17. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.